Carboplatin and Paclitaxel With or Without Bevacizumab Compared to Docetaxel, Carboplatin, and Paclitaxel in Treating Patients With Stage II, Stage III, or Stage IV Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavity Carcinoma (Cancer)

OBJECTIVES:

- Determine the maximum tolerated dose (MTD) of intraperitoneal (IP) carboplatin when
given in combination with IV paclitaxel followed by IP paclitaxel in patients with
stage III or IV ovarian epithelial, fallopian tube, or primary peritoneal cavity
carcinoma.

- Determine the MTD of IP carboplatin and IV docetaxel when given in combination with IP
paclitaxel in these patients.

- To determine the feasibility of the combination of IV paclitaxel, IP carboplatin and IV
bevacizumab on day one followed by IP paclitaxel on day eight (Part C Only).

- Determine the dose-limiting toxic effects and complications in patients treated with
these regimens.

- Evaluate the neurotoxicity of this regimen at each cycle using the FACT/GOG-NTX4
assessment tool to determine dose reduction in these patients.

- Evaluate the techniques used for intraperitoneal catheter placement, surgical
procedures, and reporting of outcomes in these patients.

OUTLINE: This is a multicenter, dose-escalation study of intraperitoneal (IP) carboplatin.
Patients in the dose-escalation phase are not eligible to enter the feasibility phase.

- Dose-escalation phase (Part A or Part B): Patients receive IP carboplatin on day 1, and
paclitaxel IV over 3 hour (part A) or docetaxel IV over 1 hour (Part B)on day 1, and IP
paclitaxel on day 8. Treatment repeats every 21 days for 6 courses in the absence of
disease progression or unacceptable toxicity.

- Feasibility phase (Part C): Patients receive IP carboplatin on day 1, paclitaxel IV on
day 1, and IP paclitaxel on day 8 in course 1 as in part A dose-escalation phase.
Beginning in course 2 and all subsequent courses, patients receive IP carboplatin on
day 1, IV paclitaxel on day 1, and IP paclitaxel on day 8 as in the dose-escalation
phase, and bevacizumab IV over 30-90 minutes on day 1. Treatment repeats every 21 days
for 6 courses in the absence of disease progression or unacceptable toxicity.

Patients are followed every 3 months for 1 year.

PROJECTED ACCRUAL: A total of 3-40 patients will be accrued for this study (3-20 in the
dose-escalation phase and 20 in the feasibility phase).